About us
TranSINETM Therapeutics, is a new, rapidly evolving biotech based in the research hub of Cambridge, UK, that is focused on the development of SINEUPsTM, a revolutionary platform technology that specifically increases the translation of target proteins in a fully plug-and-play manner. This unique and scalable platform enables TranSINETM to address unmet medical needs and build differentiated products that cannot be generated with other technologies.
TranSINETM Therapeutics has world class founders, Professor Stefano Gustincich and Professor Piero Carninci, pioneers in the fields of functional genomics and transcriptomics. The identification of SINEUPsTM, a novel class of long non-coding RNAs, was first reported in Carrieri et al., Nature. 2012;491(7424):454-457. In 2020, the value of this ground-breaking new therapeutic class was realized when TranSINETM Therapeutics received significant seed funding from Takeda Ventures Inc. and the Dementia Discovery Fund to build a pipeline of novel therapeutics across multiple disease areas including ophthalmology and neurology.
Current vacancies
Our ambition is to develop an entirely novel therapeutic approach using SINEUP® technology to treat difficult disease and achieve meaningful benefit for patients. Our team is committed to that goal and we are always keen to hear about highly innovative and enthusiastic people wishing to join us on this adventure.
We are currently recruiting for:
Get in touch
Our website will be launched soon, but in the mean time if you would like more information, please contact one of the team below:
- Dr. Sarah Cole, VP of R & D and Operations
- Dr. Marc Watson, Research Director
- Dr. Emmanuelle Astoul, Head of Licensing